Thu, May 8, 12:04 PM (15 days ago)
**Compass Therapeutics, Inc. (CMPX) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** N/A (Compass Therapeutics is a clinical-stage biopharmaceutical company and has not generated revenue from product sales). - **Net Loss:** $16.6 million for Q1 2025, compared to $10.8 million in Q1 2024. - **Operating Expenses:** Increased by 37% to $17.9 million in Q1 2025, driven by higher research and development (R&D) and general and administrative (G&A) expenses. - **Cash Position:** $113 million in cash, cash equivalents, and marketable securities as of March 31, 2025. - **Cash Burn:** $13.2 million used in operating activities in Q1 2025. **Profit Margins:** - **Gross Margin:** Not applicable (no revenue). - **Operating Margin:** -100% (operating loss of $17.9 million on no revenue). - **Net Margin:** -100% (net loss of $16.6 million on no revenue). **Cash Flow:** - **Operating Cash Flow:** Negative $13.2 million in Q1 2025. - **Investing Cash Flow:** Positive $11.6 million in Q1 2025, primarily from the sale of marketable securities. - **Financing Cash Flow:** Negative $0.8 million in Q1 2025, due to taxes paid for settlement of RSU shares. **Earnings Changes & Quarterly Performance:** - **Earnings per Share (EPS):** Negative $0.12 for Q1 2025, compared to negative $0.08 in Q1 2024. - **Quarterly Performance:** Increased R&D and G&A expenses led to a higher net loss in Q1 2025 compared to Q1 2024. **Trends & Uncertainties:** - **Trends:** Increasing operating expenses due to advancing clinical trials and growing headcount. - **Uncertainties:** Dependence on successful clinical trials, regulatory approvals, and securing additional funding. **Future Operations Impact:** - **Funding:** Expects current cash resources to fund operations into Q1 2027. - **Expenses:** Anticipates substantial increases in expenses for clinical development, commercialization, and potential acquisitions or collaborations. - **Revenue:** No revenue expected in the near future; depends on successful development and commercialization of product candidates.